[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639767":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":25,"locations":30,"responsibleParty":47,"collaborators":10,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":52,"sex":58,"minAge":59,"maxAge":10,"enrollmentInfo":60,"targetDuration":10,"studyType":63,"phases":10,"briefSummary":64,"conditions":65,"keywords":69,"overallStatus":33,"whyStopped":10,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Assiut University","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Development Cohort",null,"Adults with clinically and radiologically confirmed non-cystic fibrosis bronchiectasis (NCFB) assigned to the analytical development cohort. This cohort will be used to execute the prespecified latent class trajectory analysis (LCTA) hierarchy, identify the accepted trajectory-derived phenotype structure, assign phenotype labels according to the locked convention, and train the supervised Bronchiectasis Phenotype Identification Model (BPIM) classifier using the locked baseline disease-signature architecture. No treatment, medication, intervention, exposure, or management strategy is assigned by the study protocol.",{"label":13,"type":10,"description":14,"interventionNames":10},"Validation Cohort","Adults with clinically and radiologically confirmed non-cystic fibrosis bronchiectasis (NCFB) assigned to the analytical validation cohort. This cohort will be used only to evaluate the locked Bronchiectasis Phenotype Identification Model (BPIM) classifier after training in the development cohort. No validation-stage refitting, recalibration, predictor substitution, phenotype relabeling, threshold retuning, or post hoc classifier rescue will be performed. No treatment, medication, intervention, exposure, or management strategy is assigned by the study protocol.",[16,19,21,23],{"name":17,"affiliation":5,"role":18},"Ahmad M Shaddad, MD","PRINCIPAL_INVESTIGATOR",{"name":20,"affiliation":5,"role":18},"Aliae A. Hussien, MD",{"name":22,"affiliation":5,"role":18},"Maiada K. Hashem, MD",{"name":24,"affiliation":5,"role":18},"Alaa S. Ali, MD",[26],{"name":17,"role":27,"phone":28,"phoneExt":10,"email":29},"CONTACT","+201111171930","shaddad_ahmad@aun.edu.eg",[31],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Assiut university-Faculty of Medicine","RECRUITING","Asyut","Assiut Egypt","71515","Egypt","EG",{"type":40,"coordinates":41},"Point",[42,43],31.18368,27.18096,{"lat":43,"lon":42},[46],{"name":17,"role":27,"phone":28,"phoneExt":10,"email":29},{"type":18,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Ahmad Shaddad","Associate Professor","100639767","bronchiectasis-phenotype-identification-model-100639767",false,"NCT07599969","Bronchiectasis Phenotype Identification Model","BPIM: Bronchiectasis Phenotype Identification Model for Supervised Baseline Translation of Latent Class Trajectory Analysis-Derived Phenotypes in Non-Cystic Fibrosis Bronchiectasis","BPIM","Inclusion Criteria:\n\n* Adult patients aged 18 years or older.\n* Diagnosis of non-cystic fibrosis bronchiectasis (NCFB) based on clinical assessment and high-resolution computed tomography (HRCT).\n* Patients attending outpatient clinics, inpatient wards, or respiratory follow-up services at Assiut University Hospitals during the study enrollment period.\n* Patients suitable for baseline disease-signature assessment within the Bronchiectasis Phenotype Identification Model (BPIM) framework.\n* Ability to undergo routine clinical, functional, radiological, oxygenation, and inflammatory assessment according to the study protocol.\n* Ability to complete planned longitudinal follow-up required for latent class trajectory analysis (LCTA) and Bronchiectasis Phenotype Identification Model (BPIM) validation.\n* Written informed consent obtained from the patient or legal representative.\n\nExclusion Criteria:\n\n* Cystic fibrosis-related bronchiectasis.\n* Traction bronchiectasis due to advanced fibrotic interstitial lung disease as the dominant respiratory diagnosis.\n* Active pulmonary tuberculosis at enrollment.\n* Active nontuberculous mycobacterial pulmonary disease requiring specific treatment at enrollment.\n* Active malignancy or terminal non-respiratory illness expected to prevent planned follow-up.\n* Acute life-threatening illness preventing safe enrollment or reliable baseline assessment.\n* Recent major thoracic surgery or acute thoracic trauma interfering with baseline respiratory assessment.\n* Inability to complete required baseline disease-signature assessment according to the Bronchiectasis Phenotype Identification Model (BPIM) protocol.\n* Inability or unwillingness to complete planned longitudinal follow-up.\n* Refusal to participate.","ALL","18 Years",{"count":61,"type":62},750,"ESTIMATED","OBSERVATIONAL","The Bronchiectasis Phenotype Identification Model (BPIM) is a prospective observational development-validation study within the Assiut University bronchiectasis translational research platform.\n\nThe study evaluates whether latent class trajectory analysis (LCTA)-derived bronchiectasis phenotype classes can be translated into a supervised baseline classifier for adults with non-cystic fibrosis bronchiectasis (NCFB).\n\nLatent class trajectory analysis (LCTA) will first identify trajectory-derived phenotype classes using prospectively collected longitudinal disease-signature data. The Bronchiectasis Phenotype Identification Model (BPIM) will then be trained to predict the accepted latent class trajectory analysis (LCTA)-derived phenotype class using the locked baseline disease-signature architecture.\n\nThis study is observational and non-interventional. No treatment, medication, intervention, exposure, or management strategy is assigned by the protocol. All participants receive routine clinical care according to institutional practice and treating physician judgment.\n\nThe locked methodological disclosure, protocol, and deterministic statistical analysis plan are archived in the version-specific Zenodo record: https:\u002F\u002Fdoi.org\u002F10.5281\u002Fzenodo.20157926.",[66,67,68],"Bronchiectasis","Non-cystic Fibrosis Bronchiectasis","Bronchiectasis With Acute Exacerbation",[70,66,71,72,73,74,75,76,77,78,79,80],"Non-cystic fibrosis bronchiectasis (NCFB)","Bronchiectasis Phenotype Identification Model (BPIM)","Bronchiectasis exacerbation","Exacerbation risk","One-year exacerbation risk","Baseline risk prediction","Disease-signature model","Prospective observational cohort","Development-validation study","Latent class trajectory analysis (LCTA)","supervised phenotype classifier","2026-05-15",{"date":83,"type":84},"2026-05-20","ACTUAL",{"date":86,"type":84},"2025-09-11",{"date":88,"type":62},"2026-12-01",{"name":5,"class":6},1]